Mouse Insulin-like growth factor binding protein 2,IGFBP-2 ELISA KIT

Code CSB-E04589m
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
insulin-like growth factor binding protein 2, 36kDa
Alternative Names
Igfbp2 ELISA Kit; Igfbp-2Insulin-like growth factor-binding protein 2 ELISA Kit; IBP-2 ELISA Kit; IGF-binding protein 2 ELISA Kit; IGFBP-2 ELISA Kit; mIGFBP-2 ELISA Kit
Abbreviation
IGFBP2
Uniprot No.
Species
Mus musculus (Mouse)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.45 ng/mL-30 ng/mL
Sensitivity
0.11 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Signal Transduction
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<10%        
Three samples of known concentration were tested in twenty assays to assess.      
               
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of mouse IGFBP-2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:20 Average % 103    
Range % 98-107    
1:40 Average % 84    
Range % 80-88    
1:80 Average % 96    
Range % 92-100    
1:160 Average % 90    
Range % 86-94    
Recovery
The recovery of mouse IGFBP-2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
 
Sample Type Average % Recovery Range    
Serum (n=5) 88 84-92    
EDTA plasma (n=4) 95 90-100    
               
               
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
 
ng/ml OD1 OD2 Average Corrected    
30 2.641 2.496 2.569 2.470    
15 1.750 1.625 1.688 1.589    
7.5 1.004 1.080 1.042 0.943    
3.75 0.638 0.659 0.649 0.550    
1.8 0.329 0.313 0.321 0.222    
0.9 0.215 0.204 0.210 0.111    
0.45 0.162 0.171 0.167 0.068    
0 0.096 0.102 0.099      
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Mouse IGFBP2 ELISA Kit was designed for the quantitative measurement of Mouse IGFBP2 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 0.45 ng/mL-30 ng/mL and the sensitivity is 0.11 ng/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Inhibits IGF-mediated growth and developmental rates. IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
Gene References into Functions
  1. AAV6-mediated IGFBP-2 overexpression in the tibialis anterior (TA) muscles of 4-week-old C57BL/10 and mdx mice reduced the mass of injected muscle after 8weeks, inducing a slower muscle phenotype in C57BL/10 but not mdx mice. Analysis of inflammatory and fibrotic gene expression revealed no changes between control and IGFBP-2 injected muscles in dystrophic (mdx) mice. PMID: 27544574
  2. Peptides that disrupted p62/PKCzeta or p62/IRS-1 inhibited IGF-I/IGFBP-2 stimulated PKCzeta activation, vimentin phosphorylation, PTEN tyrosine phosphorylation, AKT activation, and osteoblast differentiation. PMID: 26773517
  3. In human whole blood cells, methylation of IGFBP2 at the homologous CpG site was increased in obese men with impaired glucose tolerance. In conclusion, our data show that increased methylation of hepatic Igfbp2 during infancy predicts the development of fatty liver later in life and is linked to deterioration of glucose metabolism. PMID: 27126637
  4. IGFBP2 not only is a driver of glioma progression and a prognostic factor but is also required for tumour maintenance and thus represents a viable therapeutic target in the treatment of glioma. PMID: 27125842
  5. that the lacking the Arg-Gly-Asp-domain has a major influence on the pleiotropic effects of IGFBP-2 and suggest that somatic growth and time of sexual maturity or somatic growth and life expectancy are less closely related than thought previously PMID: 26507795
  6. Data (including data from studies in knockout mice) suggest, as osteoblasts differentiate, early induction of AMPK in response to IGF-I/IGFBP-2 is followed by suppression of AMPK as required for osteogenesis; activation of AMPK stimulates autophagy. PMID: 26556533
  7. estrogen deficiency has a profound effect on body and bone composition in the absence of IGFBP-2 and may be related to changes in fibroblast growth factor 21. PMID: 26230658
  8. Impaired glucose clearance in female IGFBP-2 transgenic mice is dependent on the presence of the RGD motif and that translocation of GLUT4 in the muscle may be regulated by IGFBP-2 via RGD-dependent mechanisms. PMID: 26105006
  9. protein(s) that associated with RPTPbeta in response to IGF-I and IGFBP-2 in vascular smooth muscle cells PMID: 25787077
  10. The results suggest that stimulation of differentiation is an important mechanism by which IGFBP-2 regulates the acquisition of normal bone mass in mice. PMID: 24839202
  11. PPARalpha controls IGF-1 signalling through the up-regulation of hepatic Igfbp-2 transcription during fasting. PMID: 25695641
  12. IGFBP2 is a critical cell-autonomous factor that promotes the survival and migration of acute leukemia cells. PMID: 24191913
  13. IGFBP-2 plays an IGF-I-dependent and -independent role in the brain's acute (neuroprotection) and chronic (tissue remodeling) response to hypoxic-ischemic injury. PMID: 24359611
  14. physiological levels of IGFBP2 are neither sufficient to mimic nor required for the physiological action of leptin PMID: 24424049
  15. Igfbp2-5 are expressed in distinct and complementary patterns during cochlear development. PMID: 23813480
  16. These findings demonstrate that the HBD2 domain of IGFBP-2 is the primary region that accounts for its ability to inhibit adipogenesis and that a peptide encompassing this region has activity that is comparable with native IGFBP-2. PMID: 23981772
  17. we have identified a single polymorphic locus that affects skin and lung tumorigenesis and identify Igfbp5 and Igfbp2 as candidate modifier genes of lung tumorigenesis. PMID: 22973541
  18. IGFBP-2 bound receptor protein tyrosine phosphatase beta, which led to its dimerization and inactivation. Analysis of aortas obtained from IGFBP-2(-/-) mice showed that receptor protein tyrosine phosphatase beta was activated. PMID: 22869525
  19. findings suggest that insulin upregulates IGFBP-2 expression through a PI3K/mTOR/C/EBP-alpha pathway in white adipocytes PMID: 22410287
  20. Data from transgenic mice suggest that hepatic leptin signaling (i.e., direct action of leptin on hepatocytes) is not required for leptin up-regulation of plasma levels of IGFBP-2; intact vagus nerve is also not required. PMID: 22202803
  21. IGFBP-2 is an important regulator of osteoclastogenesis. PMID: 22006816
  22. IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells. PMID: 21821709
  23. the HBD peptide of IGFBP-2 has anabolic activity by activating IGF-I/Akt and beta-catenin signaling pathways PMID: 21372140
  24. The present study was aimed at determining IGFBP2 mRNA levels in adipose tissue in conditions of insulin resistance such as aging and obesity. PMID: 20730703
  25. We propose that Igfbp2 mediates epidermal progenitor cell expansion and therefore represents an epidermal progenitor cell-specific target of Hedgehog signaling that promotes basal cell carcinoma development PMID: 20858761
  26. IGFBP-2 significantly inhibits postnatal skeletal myofiber growth by decreasing myogenic proliferation and protein accretion and enhances glycolytic muscle metabolism PMID: 20501873
  27. Overexpression of IGFBP2 by an adenovirus reversed diabetes in insulin-resistant and diet-induced obese mice, as well as insulin-deficient streptozotocin-treated mice. PMID: 20074524
  28. Data show that IGFBP-2 potently separates hypertrophic and hyperplastic effects of GH/IGF-I excess on adrenocortical cells. PMID: 12409314
  29. During cell differentiation, secretion is controlled by hormones in mouse mammary epithelial cells. PMID: 12914536
  30. effect of IGFBP-2 overexpression on the activity of various antioxidative enzymes in two malignant cell lines PMID: 14710363
  31. menin regulates the expression of the endogenous IGFBP-2 gene at least in part through the promoter of IGFBP-2. PMID: 15044367
  32. intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment localize to the cell nucleus PMID: 15474485
  33. IGFBP2 expression is responsible for increased insulin receptor substrate-1 phosphorylation in mesangial cells from mice susceptible to glomerulosclerosis PMID: 16556765
  34. IGFBP-2 may regulate bone turnover in both an IGF-I-dependent and -independent manner. PMID: 18276763
  35. IGF axis as key mechanisms underlying nephropathic responses of mesangial cells to Ang II and high glucose. PMID: 18392786
  36. Results suggest that the growth-promoting role of IGFBP-2 in prostate cancer is inhibited by its intracellular interaction with PAPA-1. PMID: 19095771
  37. IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis PMID: 19142966

Show More

Hide All

Subcellular Location
Secreted.
Tissue Specificity
Highly expressed in adult liver, but also in kidney, lung, brain, spleen, testis and ovary.
Database Links
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1